PGP and non-small cell lung carcinoma: An example is a trial that evaluated P-gp inhibitors in non-small cell lung cancer, transporters such as Multidrug Resistance Associated Protein 1 (MRP1) or Breast Cancer Resistance Protein (BCRP), other than P-gp, might have accounted for the drug resistance [3,17].